CorMedix board greenlights $75M buyback program through 2027; Q1 2026 start
CorMedix’s board approved a $75M share repurchase program through December 31, 2027, with buybacks starting as early as Q1 2026, supported by a $150M cash balance and 79.3M shares outstanding. In Q4, DefenCath sales in outpatient dialysis and newly acquired Melinta products are expected to bolster revenues.
1. Board Approves $75M Buyback Program
CorMedix’s board approved a multi-year share repurchase program authorizing up to $75 million in common stock buybacks through December 31, 2027, with repurchases expected to begin in Q1 2026. The program leverages the company’s $150 million cash balance and 79.3 million shares outstanding while preserving capital for growth initiatives.
2. Q4 Outlook Supported by DefenCath and Melinta
DefenCath sales in outpatient hemodialysis are driving revenue growth in Q4, reflecting increased adoption of the company’s infection prevention therapy. Newly acquired Melinta products are anticipated to add further upside contributions to overall quarterly sales.
3. Senior Insider Share Sale
Executive Vice President and General Manager of Healthcare Janet Dillione sold 10,000 shares for proceeds of $68,800 in late January. While modest in dollar terms, the round-lot sale is monitored by investors as part of routine compensation management at smaller-cap biopharmaceutical firms.